Initiation Of Phase III First-Line Trial Of Avelumab

The clinical development program for avelumab now includes more than 1,400 patients who have been treated across more than 15 tumor types, including breast cancer, gastric/gastro-esophageal (GEJ) cancers, head and neck cancer, Merkel cell carcinoma, melanoma, NSCLC, ovarian cancer, renal cell carcinoma and urothelial (e.g., bladder) cancer.11/05/2015
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news